Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
68.82%
Operating Margin
27.49%
Net Margin
41.28%
Efficiency Metrics
Revenue per Expense Ratio
1.38
R&D as % of Revenue
17.67%
Earnings Quality
EBITDA Margin
27.86%
Income Tax Rate
11.53%
EPS
13.8800000000
Balance Sheet Analysis
Current Ratio
1.16
Cash Ratio
0.50
Working Capital
$7.21B
Debt to Equity
0.43
Debt to Assets
17.51%
Equity Ratio
41.04%
Cash Flow Analysis
Operating Cash Flow Ratio
26.76%
Free Cash Flow Ratio
21.43%
CapEx to Revenue
5.33%
Dividends Paid
$11.77B
Stock Buybacks
$5.05B
Total Shareholder Returns
$16.82B
Cash Position Change
69.59%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 3.94%
Increased R&D investment by 6.46%
Detailed Growth Metrics
Core Performance
Revenue
6.46%
Net Income
95.94%
EPS
102.33%
Operating Income
0.93%
Operational Efficiency
R&D Expenses
6.46%
SG&A Expenses
5.60%
Operating Cash Flow
7.54%
Free Cash Flow
6.19%
Balance Sheet Health
Assets
-10.58%
Debt
-26.01%
Book Value per Share
-7.62%
Inventory
8.89%
Shareholder Returns
Dividends per Share
3.94%
Shares Outstanding
-3.06%
Long Term Trends
3Y Revenue/Share
7.15%
5Y Revenue/Share
9.69%
3Y Dividend/Share
16.69%
5Y Dividend/Share
30.28%